نتائج البحث - Denis Soulières

تنقيح النتائج
  1. 1
    The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements

    The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements حسب Pierre-Olivier Gaudreau, John Stagg, Denis Soulières, Fred Saad

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study

    Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study حسب Luis Corrales, Denis Soulières, Xiaoduan Weng, Mustapha Tehfé, Marie Florescu, Normand Blais

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects

    Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects حسب Christian Kollmannsberger, Denis Soulières, Ralph Wong, Alissa Scalera, Rania Gaspo, Georg A. Bjarnason

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

    Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the He... حسب Denis Soulières, Neil Senzer, Everett E. Vokes, Manuel Hidalgo, Sanjiv S. Agarwala, Lillian L. Siu

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Neutrophil count is associated with survival in localized prostate cancer

    Neutrophil count is associated with survival in localized prostate cancer حسب Houda Bahig, Daniel Taussky, Guila Delouya, Amal Nadiri, Ariane Gagnon-Jacques, Paule Bodson‐Clermont, Denis Soulières

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis

    Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis حسب Luis Paz‐Ares, Denis Soulières, I. Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer

    منشور في 2010
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab

    Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab حسب Fanny Zulay Acero Brand, Nicolas Suter, Jean‐Philippe Adam, B Faulques, Antonio Maietta, Denis Soulières, Normand Blais

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies

    KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies حسب Denis Soulières, Wenda Greer, Anthony M. Magliocco, David G. Huntsman, Sean Young, Ming‐Sound Tsao, Suzanne Kamel‐Reid

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

    Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review حسب Aly‐Khan A. Lalani, Daniel Y.C. Heng, Naveen S. Basappa, Lori Wood, Nayyer Iqbal, Deanna McLeod, Denis Soulières, Christian Kollmannsberger

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment

    Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment حسب Martin E. Blackstein, Jean‐Yves Blay, Christopher L. Corless, David K. Driman, Robert H. Riddell, Denis Soulières, Carol J. Swallow, Shailendra Verma

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer

    Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer حسب Hope S. Rugo, Alison Stopeck, Anil A. Joy, Stephen Chan, Shailendra Verma, Aña Lluch, Katherine Liau, Sinil Kim, Paul Bycott, Brad Rosbrook, Angel H. Bair, Denis Soulières

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1

    Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1 حسب Denis Soulières, Lisa Licitra, Ricard Mesı́a, Éva Remenár, Shau-Hsuan Li, А. А. Карпенко, Marie Chol, Ying A. Wang, Nadia Solovieff, Laurence Bourdeau, Dalila Sellami, Sandrine Faivre

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

    Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040) حسب Sara I. Pai, Sandrine Faivre, Lisa Licitra, Jean-Pascal Machiels, Jan B. Vermorken, Paolo Bruzzi, Viktor Gruenwald, R. Giglio, C. René Leemans, Tanguy Y. Seiwert, Denis Soulières

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study

    Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium... حسب Lillian L. Siu, Denis Soulières, Eric X. Chen, Gregory R. Pond, Soo Chin, P. Francis, Luc Harvey, M. Klein, Wenjiang Zhang, Janet Dancey, Elizabeth A. Eisenhauer, Eric Winquist

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer

    Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer حسب Kenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, Tricia Bal, Ezra E.W. Cohen, Kevin J. Harrington, Denis Soulières, Christophe Le Tourneau, Lisa Licitra, Barbara Burtness, Ramona F. Swaby

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

    Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells حسب Robert H. Vonderheide, Patricia LoRusso, Magi Khalil, Elaina M. Gartner, Divis Khaira, Denis Soulières, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, G Mariani, Tiziana Usari, Susan M. Domchek

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115

    Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical... حسب J. Maroun, K. Bélanger, Lesley Seymour, S. Matthews, James Roach, Jeanne Dionne, Denis Soulières, David J. Stewart, Rakesh Goel, Danielle Charpentier, Glenwood Goss, Eva Tomiak, J. Yau, José Jimeno, G. Chiritescu

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol

    Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol حسب Nada J. Farsi, Marie‐Claude Rousseau, Nicolas F. Schlecht, Geneviève Castonguay, Paul Allison, Phuc Félix Nguyen‐Tan, Denis Soulières, François Coutlée, Michael Hier, Sreenath Madathil, Eduardo L. Franco, Belinda Nicolau

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma

    Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma حسب Carole Fakhry, Qiang Zhang, Phuc Félix Nguyen‐Tan, David I. Rosenthal, Adel K. El‐Naggar, Adam S. Garden, Denis Soulières, Andy Trotti, Vilija N. Avizonis, John A. Ridge, Jonathan Harris, Quynh‐Thu Le, Maura L. Gillison

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

    Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma حسب Houda Bahig, F. Aubin, John Stagg, Olguta Gologan, Olivier Ballivy, Éric Bissada, Felix‐Phuc Nguyen‐Tan, Denis Soulières, Louis Guertin, Édith Filion, Apostolos Christopoulos, Louise Lambert, Mustapha Tehfé, Tareck Ayad, Danielle Charpentier, Rahima Jamal, Philip Wong

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: